Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026

Ligand Pharmaceuticals, Inc. (LGND)

Nasdaq Health Care Biotechnology S&P SmallCap 600
$306.20
+7.20 (+2.41%)
Close of Nov 06, 2026 · end-of-day data
Source: Ligand Pharmaceuticals, Inc.'s 10-K / 10-Q XBRL data on SEC EDGAR · fetched Nov 02, 2026

Revenue, net income & free cash flow

Income statement

fiscal years · USD
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue$108.97M$141.10M$251.45M$120.28M$163.56M$241.54M$196.25M$131.31M$167.13M$268.09M
Cost of revenue$5.57M$5.37M$6.34M———————
Gross profit$103.40M$135.74M$245.12M———————
Research & development$21.22M$26.89M$27.86M$55.91M$40.50M$32.10M$36.08M$24.54M$21.43M$81.18M
Operating income$43.88M$68.08M$163.73M$807.08M$37.50M$103.85M$3.04M$11.94M-$22.61M$41.00M
Interest expense$12.84M$13.46M$48.28M$35.74M$27.41M$19.62M$1.80M$656.00K$3.04M$4.71M
Pre-tax income$7.96M$57.23M$173.33M$796.64M$1.29M$72.20M$36.01M$63.66M$2.52M$158.96M
Income tax$10.33M$44.67M$30.01M$167.34M-$5.31M-$4.15M$41.23M$9.84M$6.55M$34.51M
Net income-$1.64M$12.56M$143.32M$629.30M-$2.98M$57.14M-$33.36M$52.15M-$4.03M$124.45M
EBITDA$55.17M$79.03M$176.51M$825.44M$63.19M$154.92M$54.57M$48.46M$12.63M$74.78M
EPS (basic)$-0.08$0.60$6.77$33.13$-0.18$3.44$-1.98$3.02$-0.22$6.44
EPS (diluted)$-0.08$0.53$5.96$31.85$-0.18$3.31$-1.98$2.94$-0.22$6.13
Diluted shares20.83M23.48M24.07M19.76M16.82M17.25M16.87M17.76M18.29M20.29M
Gross margin94.9%96.2%97.5%———————
Operating margin40.3%48.2%65.1%671.0%22.9%43.0%1.5%9.1%-13.5%15.3%
Net margin-1.5%8.9%57.0%523.2%-1.8%23.7%-17.0%39.7%-2.4%46.4%

Balance sheet

fiscal years · USD
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$18.75M$20.62M$117.16M$71.54M$47.62M$19.52M$45.01M$22.95M$72.31M$174.93M
Short-term investments$122.30M$181.04M$601.22M$998.32M$363.57M$321.59M$166.86M$147.35M$183.86M$558.59M
Receivables$14.70M$25.60M$55.85M$30.39M$56.85M$85.45M$30.42M$32.92M$38.38M$59.60M
Inventory$1.92M$4.37M$7.12M$7.30M$26.49M$27.33M$13.29M$23.97M$14.11M$9.13M
Total current assets$163.05M$237.02M$870.54M$1.12B$500.56M$464.75M$263.60M$237.43M$331.56M$832.27M
Goodwill$72.21M$85.96M$86.65M$95.23M$189.66M$105.67M$0$103.37M$105.25M$101.54M
Total assets$601.59M$671.02M$1.26B$1.49B$1.36B$1.30B$762.67M$787.22M$941.77M$1.56B
Total current liabilities$227.13M$238.87M$82.25M$17.00M$100.11M$41.66M$98.81M$16.78M$37.11M$37.45M
Long-term debt————————$0$446.19M
Total debt————————$0$446.19M
Total liabilities$230.73M$252.37M$699.89M$727.68M$652.76M$476.43M$165.18M$86.30M$111.33M$543.42M
Shareholders' equity$341.29M$399.79M$560.91M$767.23M$709.52M$821.16M$597.49M$700.91M$830.44M$1.02B

Cash flow

fiscal years · USD
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow$60.73M$88.57M$194.06M-$29.34M$54.59M$78.80M$137.85M$49.58M$97.05M$49.36M
Capital expenditures$1.85M$2.16M$887.00K$2.55M$4.46M$8.76M$17.92M$3.52M$1.82M$452.00K
Free cash flow$58.88M$86.41M$193.17M-$31.89M$50.13M$70.04M$119.93M$46.06M$95.23M$48.91M
Investing cash flow-$134.41M-$79.18M-$423.27M$466.92M$231.65M$30.52M$163.62M-$11.68M-$143.66M-$377.32M
Financing cash flow-$4.99M-$7.52M$328.58M-$485.17M-$310.55M-$137.76M-$275.99M-$59.95M$97.14M$428.22M
Share buybacks$3.90M$1.97M$122.87M$453.05M$78.00M$0$0$0$0$15.00M
Stock-based compensation$18.89M$24.91M$20.85M$24.52M$30.73M$38.78M$60.28M$25.74M$41.09M$46.85M
Depreciation & amortization$11.29M$10.96M$12.78M$18.36M$25.69M$51.07M$51.53M$36.52M$35.24M$33.77M

Quarterly figures are rebuilt from the year-to-date totals companies report — Q4 is the full year minus the first nine months, since no 10-Q is filed for it. Values are as filed; later restatements replace earlier ones. Fiscal years are labelled by the calendar year in which they end.